Webinar: STRIDE registry: Applying real-world evidence to expand the clinical picture of nonsense mutation Duchenne muscular dystrophy (nmDMD)
The real-world evidence from the Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry, an observational registry of patients with nmDMD receiving a mutation-specific Duchenne muscular dystrophy (DMD) therapy, are discussed in this PTC Therapeutics-sponsored webinar
The results of a propensity-score matched analysis of the non-ambulatory patients from the STRIDE Registry are presented
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This is a recording of our live webinar. This webinar recording has been chapterized to enable ease of viewing.
Register now to unlock the content
Register now to access the content on this page
If not, register below
GL-DMD-0426 | October 2021
Sign in or register to access exclusive content on this site